In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Tupa BasuroyDepartment of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH USA.
Treg GrubbDepartment of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH USA.
Xingping QinJohn B. Little Center for Radiation Sciences, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Kylee MadisonDepartment of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH USA.
Autumn HallProteomics and Metabolomics Core, Cleveland Clinic, Cleveland, OH, USA.
Belinda WillardProteomics and Metabolomics Core, Cleveland Clinic, Cleveland, OH, USA.
Sakari VanharantaTranslational Cancer Medicine Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-5619-7963 Kristopher A SarosiekDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Srinivas R ViswanathanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-1856-3023 Abhishek A ChakrabortyDepartment of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH USA.
Funding
Developmental regulation of apoptosis as a modifiable driver of radiotherapy-induced neurocognitive impairment in pediatric patientsR37CA248565 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Kristopher Andrew Sarosiek · 2020 to 2026
$2.6MIdentifying targetable apoptotic vulnerabilities for the treatment of AL amyloidosisR01DK125263 · NIDDK · HARVARD SCHOOL OF PUBLIC HEALTH · PI SAROSIEK, KRISTOPHER ANDREW · 2020 to 2023
$1.4MNCI NIH HHS R37 CA248565NIDDK NIH HHS R01 DK125263
6 · The paper itselfAbstract
Identifiers
PMID41415469
PMCPMC12710959
What Socratic holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390